<DOC>
	<DOC>NCT02868099</DOC>
	<brief_summary>The objective is to evaluate the efficacy and safety of romiplostim for injection in adlut subjects with persistent or chronic primary immune thrombocytopenia (ITP).</brief_summary>
	<brief_title>Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Diagnosed with immune thrombocytopenia (ITP) for at least 6 months prior to signing the informed consent form (ICF). Subject is ≥ 18 years old while signing the ICF. Patients who have no response or relapsed after splenectomy. Or patients who have not been splenectomised and have no response or relapse to at least 1 prior treatment for immune thrombocytopenia (ITP). The mean of 3 scheduled platelet counts taken during the screening period must be: &lt; 30 ×10^9/L, with none &gt;35×10^9/L. Any known history of bone marrow stem cell disorder. Any abnormal bone marrow findings other than those typical of ITP. Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, and no treatment or active disease within 5 years prior to signing the ICF.. Received hematopoietic growth factors (e.g., granulocyte colonystimulating factor, macrophage colonystimulating factor, erythropoietin, interleukin11) for any reason within 4 weeks prior to signing the ICF. Received myeloproliferative leukemia (MPL) stimulation product other than the subject who had suspended recombinant human thrombopoietin (rHuTPO) for injection for 4 weeks before signing ICF. Received any antimalignancy agents (e.g., cyclophosphamide, 6mercaptopurine, vincristine, vinblastine, Interferonalfa) for any reason within 8 weeks prior to signing the ICF. Received any monoclonal antibody drugs (e.g., rituximab) for any reason within 14 weeks prior to signing the ICF. Less than 4 weeks since end of any clinical trials about therapeutic drug or device prior to signing the ICF. Pregnant or breastfeeding. In the opinions of the principal investigator or investigators, the patients are not suitable for participation in this trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>